New chemo cocktail shows promise for rare brain tumor patients
NCT ID NCT04755023
First seen May 13, 2026 · Last updated Jun 18, 2026 · Updated 8 times
Summary
This study tested a combination of two chemotherapy drugs (BCNU and TMZ) given before radiation therapy in 53 people newly diagnosed with a rare type of brain cancer called anaplastic oligodendroglioma. The goal was to see how well the drugs shrank tumors and to learn more about genetic markers that might predict treatment response. The approach aims to improve disease control and guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC OLIGODENDROGLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.